

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 850 651 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**25.02.2004 Bulletin 2004/09**

(51) Int Cl.<sup>7</sup>: **A61L 27/00**, A61L 31/00,  
B05C 1/00

(21) Application number: **97203933.3**

(22) Date of filing: **15.12.1997**

**(54) Method and Apparatus for applying drug-release coatings**

Verfahren und Vorrichtung zum Anbringen medizinische Wirkstoffe freisetzender Beschichtungen

Méthode et appareil pour appliquer des couches délivrant des agents médicaux

(84) Designated Contracting States:  
**DE ES FR GB IE IT NL**

(30) Priority: **20.12.1996 US 33443 P**

(43) Date of publication of application:  
**01.07.1998 Bulletin 1998/27**

(73) Proprietor: **SCHNEIDER (USA) INC.**  
**Plymouth, Minnesota 55442 (US)**

(72) Inventor: **Ding, Ni**  
**Plymouth, Minnesota 55446 (US)**

(74) Representative: **Williams, Ceili et al**  
**Stevens Hewlett & Perkins**  
**Halton House**  
**20/23 Holborn**  
**London EC1N 2JD (GB)**

(56) References cited:

<b>EP-A- 0 533 262</b>	<b>EP-A- 0 623 354</b>
<b>EP-A- 0 675 315</b>	<b>WO-A-89/04682</b>
<b>WO-A-91/17724</b>	<b>WO-A-92/15286</b>
<b>WO-A-94/21308</b>	<b>US-A- 5 053 048</b>
<b>US-A- 5 304 121</b>	<b>US-A- 5 356 433</b>

**EP 0 850 651 B1**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

## Description

[0001] This application claims priority to U.S. Provisional Application Serial No. 60/033,443 filed December 20, 1996.

## Field of the Invention

[0002] This invention relates generally to drug-releasing coatings for medical devices which are inserted or implanted into the body. More particularly, the invention is directed to a method for applying drug-releasing coatings to medical devices in which a polymer is dissolved in a first solvent (solvent A) to form a polymer system and a drug is dissolved in a second solvent (solvent B) to form a drug system.

## Background of the Invention

[0003] In prior art methods, a composition comprising a mix of a drug and a polymer in a solvent is applied to the device to form a substantially uniform layer of drug and polymer; *i.e.* a layer in which the drug is dispersed in the polymer in a substantially uniform manner. Depending upon the types of polymers and drugs employed, finding a common solvent for these two constituents can be problematic. Where a common solvent for the drug and polymer is not available, attempts have been made to micronize the drug into small particles so that it can be suspended in the polymer solution. However, micronization can be time consuming, and may result in a loss of desired therapeutic properties of the drug. Therefore, a method of more easily putting both the drug and polymer into solution to obtain a drug releasing coating for medical devices is needed. Also needed is a method of applying a drug/polymer coating without having to combine the drug and polymer in a common solution or suspension.

## Summary of the Invention

[0004] The methods disclosed herein apply generally to implantable prostheses, especially expandable prostheses such as balloon expandable stents and self-expanding stents. Stents coated according to this invention may be, for instance, plastically deformable or self-expanding. In certain embodiments, the methods avoid the necessity of micronizing a drug before it is applied to a stent. In other embodiments, drug particulates can be utilized. The present invention can also be used where there is no common compatible solvent for both the polymer and the drug.

[0005] Broadly, the invention relates to a method of applying drug-release coatings containing a drug and a polymer, in which the drug is distributed in the polymer in a substantially uniform manner. A polymer can be dissolved in a first solvent (solvent A) to form a thermodynamically stable polymer system substantially free of bi-

ologically active materials (*e.g.*, less than about 1% by weight of the polymer) and a drug can be dissolved in a second solvent (solvent B) to form a drug system substantially free of polymers (*e.g.*, less than about 1% by weight of the drug). Solvent B can be the same as or different than solvent A. Different solvents are generally used when the drug has very low solubility in the polymer solution and no common solvent would be found for both the drug and polymer. By applying the polymer system and drug system separately and simultaneously to the surface of the medical device, the method forms a composite of the polymer and drug, *i.e.*, a distribution of the drug throughout a network of polymer. Such composite may be substantially homogenous. The method of the present invention avoids the need for micronizing the drug prior to mixing it with the polymer to form the composite of drug and polymer. Although the method provides a coating or a layer of a coating which comprises a composite of the drug and polymer, it avoids the need for mixing the drug and polymer in one solution before applying the coating to the device.

[0006] A coating can be applied on a device, particularly a stent, by separately spraying the polymer system and the drug system. Methods of coating stents are disclosed in U.S. Patent Nos. 5,837,313 and 6,120,536. The coatings of the invention can be accomplished by spraying the polymer and drug systems simultaneously, as further described below.

[0007] Depending upon the coating thickness desired, multi-step coatings may be applied. Depending upon the solvent volatility, a waiting period may be required during the spraying or dipping process, or heat may be applied through a heat gun, a heat lamp or a heat chamber to facilitate the evaporation of the solvent (s).

[0008] In certain embodiments, it is not necessary for a drug to be dissolved in solvent B. Fine particles can be mixed, preferably suspended, in the solvent, and the coating can be applied as described herein. In some cases, three or more systems can be utilized. For instance, a third spraying or dipping system containing pure solvent A or B can smooth the coating surface, if the solvent of the third system is compatible with the polymer matrix, or a third spraying or dipping system containing a second elutable agent such as a drug. Polyethylene glycol, sugar, salt in solvent (which can be same or different than solvents A and B), can be applied to the stent. The resulting drug release profile, where two or more drugs are applied, can result in the different drugs being released simultaneously or sequentially.

[0009] A suitable sequence according to this invention could be one application of a polymer solution and a drug solution or suspension followed by one application of pure solvent. Alternatively, the sequence could be three parallel spraying systems. The number of cycles in each operation could be half, one, two or more. It is appreciated that those skilled in the art will find numerous combinations of coating orders and sequences

for dual or multiple coating systems without departing from the inventive concept. The coating system can be hand-operated or automated to achieve different combinations.

### **Brief-Description of the Drawings.**

#### **[0010]**

FIGURE 1 is a photograph showing the results of the comparative Example;  
 FIGURE 2 is a photograph showing the results of Example 1;  
 FIGURE 3 is a photograph showing the results of Example 2;  
 FIGURES 4 and 5 are scanning electron microscope photographs showing the results of the Comparative Example in an unstressed state and a post-stressed state, respectively;  
 FIGURES 6 and 7 are scanning electron microscope photographs showing the results of Example 1 in an unstressed state and a post-stressed state, respectively;  
 FIGURES 8 and 9 are scanning electron microscope photographs showing the results of Example 2 in an unstressed state and a post-stressed state, respectively;  
 FIGURE 10 shows a stent prior to coating;  
 FIGURES 11 and 12 sequentially illustrate an embodiment of the present invention;  
 FIGURES 13 and 14 sequentially illustrate an alternative embodiment of the present invention;  
 FIGURE 15 graphically compares elution rates for the Comparative Example, Example 1 and Example 2; and  
 FIGURE 16 is a graphical comparison of the elution rates of Examples 4a, 4b, 5 and 6.

### **Detailed Description of the Invention**

**[0011]** Polymers suitable for the present invention will preferably be hydrophobic biostable elastomeric materials which do not degrade and which minimize tissue rejection. Furthermore, the materials are preferably ones which will undergo encapsulation by tissue adjacent to the stent implantation site. Polymers suitable for such coatings include silicones (e.g., polysiloxanes and substituted polysiloxanes), polyurethanes (including polycarbonate urethanes), thermoplastic elastomers in general, ethylene vinyl acetate copolymers, polyolefin elastomers, EPDM rubbers and polyamide elastomers. The above-referenced materials are considered hydrophobic with respect to the contemplated environment of the invention.

**[0012]** Non-limiting examples of other polymers which are suitable for use in the present invention include bioabsorbable polymers such as polylactic acid, polyglycolic acid, polycaprolactone, polylactic acid - polyethyl-

ene oxide copolymers, cellulose, and the like. Other non-limiting examples of polymers that are suitable for use in the present invention also include biostable plastic materials such as acrylic polymers and its derivatives, nylon, and polyesters.

**[0013]** Non-limiting examples of drugs suitable for use in the present invention include antithrombotics, anticoagulants, antiplatelet agents, thrombolytics, antiproliferatives, anti-inflammatories, agents that inhibit hyperplasia and in particular restenosis, smooth muscle cell inhibitors, antibiotics, growth factors, growth factor inhibitors, cell adhesion inhibitors, cell adhesion promoters and drugs that may enhance the formation of healthy neointimal tissue, including endothelial cell regeneration. The positive action may come from inhibiting particular cells (e.g., smooth muscle cells) or tissue formation (e.g., fibromuscular tissue) while encouraging different cell migration (e.g., endothelium) and tissue formation (neointimal tissue).

**[0014]** The drug used in the invention may or may not be micronized. When the drug is not micronized, the particle size of the drug can be greater than about 10µm. When the drug is micronized, the drug particle size is preferably 5-12 µm and more preferably about 5 µm.

**[0015]** The devices suitable for the invention include without limitation a variety of medical devices such as catheters, shunts, stents (e.g. self expandable or balloon expandable vascular or non-vascular stents), heart valves, grafts, and artificial organs or prostheses. The devices may have polymeric, metallic or ceramic surfaces.

**[0016]** The preferred materials for fabricating stents, particularly braided stents, such as that shown in FIGURE 10, include metals such as stainless steel, tantalum, titanium alloys including nitinol (a nickel titanium, thermomemorial alloy material), DFT materials such as shown in U.S. 5,630,840 and certain cobalt alloys including cobalt-chromium-nickel alloys such as Elgiloy® and Phynox®. Bioabsorbable materials may also be used to form the stent structure, such as polylactic acid. Further details concerning the fabrication and details of other aspects of the stents themselves are found in U. S. Patent Nos. 4,655,771 and 4,954,126 to Wallsten and 5,061,275 to Wallsten *et al.*

**[0017]** Solvents which can be used in the present invention will preferably be compatible with the polymer or drug with which they are mixed. For instance, the polymer will preferably be fully dissolvable in the solvent with which it is mixed, and the drug will preferably be fully dissolvable in the solvent with which it is mixed. However, it is contemplated that certain embodiments of the present invention will include particulate drugs, such as heparin, mixed in solvent. Where drugs are in particulate form, the drug will preferably be suspended in the solvent. Nonlimiting examples of solvents that can be used according to this invention include tetrahydrofuran, methanol, methyl ethyl ketone, chloroform, methylene chloride, acetonitrile, and water.

[0018] The following examples describe embodiments of the invention in which the coatings were applied to the medical devices by spray coating (Comparative Example and Examples 1-3) or by dip coating (Examples 4-6).

### Comparative Example

[0019] A silicone-xylene mixture (~34% solid weight from Applied Silicone Corporation) was weighed, and the solid silicone content was calculated. A ratio of  $W_{dex}/W_{silicone\ solid} = 0.1$  was used in the preparation. Here "dex" or "DEX" refers to dexamethasone (Upjohn, Dexamethasone USP, CAS # 50-02-2). The volume amount of tetrahydrofuran (THF) (HPLC grade, Aldrich or EM Science) used was determined by multiplication of 20 with the weight of the solid silicone. DEX was first dissolved in THF and then transferred to a silicone-xylene mixture. A crosslinker agent was added and the solution was mixed well. A braided stent was coated by spraying multiple cycles of the homogeneous solution so prepared on the stent in an expanded state. The coated stent was then moved to a convection oven and cured at 150°C for 45 minutes. It was then treated with argon gas plasma according to the procedure described in US Patent No. 5,879,697. The results are shown in FIGURES 1, 4 and 5. FIGURES 1 and 4 are photographs of the coating in an unstressed state, i.e., before the stent was expanded or contracted. FIGURE 5 is a photograph of the coating after the coated stent was mechanically stressed, i.e., following contraction and expansion of the stent.

### Example 1

[0020] A 5% (w/w) solution of silicone solid in THF was prepared by adding the required THF and crosslinker agent into the silicone mixture. A separate 0.5% (w/w) solution of DEX in THF was prepared by adding THF into a beaker containing DEX. The ratio of  $W_{dex}/W_{silicone\ solid}$  was 0.1. A badger 150-4 spray system was used with two reservoirs filled with two different solutions. The coating of the stent in an expanded state was accomplished by spraying one cycle of silicone solution, waiting for a short period of time (about 30 seconds), and spraying one cycle of DEX solution, waiting for a short period of time (about 30 seconds), and then repeating the spraying sequence. The very last spray cycle was silicone solution. For a coating thickness of 30 micron, about 30 cycles each were applied. The number of spray cycles used depended on the solution viscosity, the droplet size and the flow rate. The coated stent was then moved to a convection oven and cured at 150°C for 45 minutes. It was then argon gas plasma treated. The results are shown in FIGURES 2, 6, and 7. FIGURES 2 and 6 are photographs of the coating in an unstressed state. FIGURE 7 is a photograph of the coating after the coated stent was mechanically stressed.

### Example 2

[0021] The process used to prepare this example was similar to the process utilized in Example 1 except that DEX was dissolved in methanol, which is a poor solvent for silicone. The ratio of  $W_{dex}/W_{silicone\ solid}$  was maintained at 0.1 in the preparation. The results are shown in FIGURES 3, 8, and 9. FIGURES 3 and 8 are photographs of the coating in a unstressed state. FIGURE 9 is a photograph of the coating after the coated stent was mechanically stressed, i.e., expanded and contracted.

### Example 3

[0022] The coated stents prepared in the Comparative Example, Example 1 and Example 2 were cut into 2 cm segments and put into 100 ml of polyethylene glycol (MW=400, Aldrich) and water mixture (40/60, v/v). The solution was changed frequently when sampling the solution. The DEX concentration was analyzed by using a Shimadzu high performance liquid chromatography instrument, operated with a UV detector at the wavelength of 254 nm. A C-8 column was used in the analysis. Table 1 and FIGURE 15 show the DEX release data over one month for the coated stents. All three preparations in the Comparative Example, Example 1 and Example 2 prolonged the drug release and had similar release profiles.

Table 1:

Release Rate Data ( $\mu\text{g}/\text{cm}^2/\text{hr}$ )			
Time (days)	Comp. Ex.	Ex. 1	Ex. 2
0.08	6.25	27.46	14.88
1.73	0.66	3.32	0.83
3.77	0.38	1.08	0.36
4.75	0.38	0.91	0.33
11.81	0.24	0.44	0.21
14.08	0.24	0.34	0.22
16.94	0.23	0.27	0.20
19.08	0.22	0.28	0.22
21.08	0.21	0.19	0.18
26.08	0.15	0.17	0.14
28.00	0.11	0.10	0.12
32.06	0.17	0.16	0.15

[0023] An embodiment of the present invention involving spray coating is sequentially illustrated in Figures 11 and 12. The drug-release coating apparatus 2 has a stent rotating element 4 and a spraying element 6.

[0024] A stent 8 is mounted on the stent rotating element 4 by clamping it at both ends to supporting rod el-

elements **24'**, **24''**, which are typically alligator clamps. Preferably, stent **8** will be clamped in a position which is at least partially expanded or fully expanded such that its interior remains empty allowing spray coating to adhere to both the exterior and the interior surface of stent **8**. Rod elements **24'**, **24''** do not traverse the interior of stent **8**. Motor **10** rotates the rod elements **24'**, **24''** thereby rotating stent **8**. Supporting rod **12** supports the stent rotating element **4**.

**[0025]** Spraying element **6** has a structural support **14** on which a first spray canister **16** and a second spray canister **18** are mounted. First spray canister **16** is fluidly connected to first spray dispenser **20** and second spray canister **18** is fluidly connected to second spray dispenser **22**. Gas supply means **26**, **28** are connected to the spraying devices to provide gaseous means to propel the polymer and drug solutions.

**[0026]** The first and second spray canisters **16**, **18** can be mounted on structural support **14** on a track (not shown) to enable longitudinal movement back and forth. In a simplified case, a hand can act as a support **14**. In this embodiment, canisters **16**, **18** are fixed at a predetermined distance from one another, so that they move to and from equidistant from one another. The hollow arrow in FIGURE 11 shows canisters **16**, **18** prior to leftward movement. Spray will begin once spray dispensers **20**, **22** oppose the stent **8**. The solid arrow in FIGURE 12 shows canisters **16**, **18** beginning their course back to the right, again beginning to spray once dispensers **20**, **22** oppose the stent. This sequence can be repeated multiple times, as desired.

**[0027]** In this embodiment, first spray canister **16** can hold polymer in solvent and be free of drug, while second spray canister **18** can hold drug in solvent and be free of polymer, or *vice versa*.

**[0028]** FIGURES 13 and 14 sequentially illustrate a different embodiment of the present invention. The reference numerals in this embodiment have the same meaning as those in the previous embodiment shown in FIGURES 11 and 12.

**[0029]** The first and second spray canisters **16**, **18** can be mounted on structural support **14** on two tracks (not shown) to enable longitudinal movement back and forth. In this embodiment, canisters **16**, **18** can move to and from independent from one another. In FIGURE 13, the solid arrow shows the first canister **16** moving to the left and spraying the stent, while the hollow arrow indicates second canister **18** in a stationary position with the potential to move to the left. First canister **16** continues to the left and then stops beyond the stent and assumes a stationary position (not shown). Then, as shown in FIGURE 14, the second canister **18** moves to the left to spray the stent and then rests to the left of the stent. Thereafter, the first canister **16** can move to the right, later followed by the second canister **18**, and the process can be repeated as desired.

**[0030]** Other processes according to this invention can include the first canister **16** going to and from while

the second canister **18** is at rest beyond the stent, followed by the second canister going to and from while the first canister **16** is at rest beyond the stent. Other non-limiting variations include having canisters **16** and **18** move simultaneously but spaced apart from one another, or having canisters **16** and **18** criss-cross while spraying.

**[0031]** In addition to spray coating, the coatings of this invention can be applied by dipping the medical device in 1) a polymer dissolved in a first solvent and 2) a drug dissolved in a second solvent. The device can be repeatedly dipped into the polymer solution and drug solution until a coating of the desired thickness is achieved. In general, the polymer will shrink and swell, and the drug will recrystallize or redistribute in the subsequent dipping steps depending upon the relative solvability of the solvents to the polymer and drug. In order to ensure uniformity of the coating on the device, certain steps can be taken. These steps include, without limitation: choosing a solvent with a low viscosity index, choosing a polymer above its entanglement molecular weight such that the inner polymer layer(s) will swell but will not be easily dissolved, blow drying the coating after each dipping, horizontally coating the device, rotating the device during drying and using short coating times.

**[0032]** The following examples illustrate embodiments of the invention which were prepared by dipping.

#### Example 4

**[0033]** 15 grams of a silicone dispersion from Applied Silicone Corp. (#40000), containing 35% solids, was weighed. 0.52 grams of dexamethasone (DEX) (Upjohn, Lot #719kT) was dissolved in 15 mL of tetrahydrofuran (THF). The drug solution was added to the silicone dispersion and stirred until a homogeneous solution was formed.

**[0034]** A stent graft (Example 4a) was dipped into the solution and air dried in its horizontal position. The coating weight for this sample was 10.8 mg/cm<sup>2</sup>. Due to gravity, the coating became uneven. To obtain a more uniform coating, a second stent graft (Example 4b), after being dipped into the solution, was rotated horizontally as it air dried. The coating weight for this sample was 13.5 mg/cm<sup>2</sup>. After sitting at room temperature for about 1.5 hours, the coated samples were oven cured at 150°C for 1 hour.

**[0035]** The grafts were cut into 2 cm pieces and their release rates were studied by immersing the pieces in a 25/75 v/v aqueous solution of polyethylene glycol (PEG) (MW=400 from J.T. Baker). The solutions were periodically sampled and replaced with fresh solution. The amount of DEX released was quantified by a Shimadzu High Performance Liquid Chromatography (HPLC), using a C8 column (Phase Separation Ltd) with a mobile phase of acetonitrile/H<sub>2</sub>O (1:1 v/v), a flow rate of 1 ml/min and a UV detector at a wavelength of 254 nm. The release rates for these two samples are pre-

sented in Table 2. The data shows that the coated samples can provide prolonged drug release (see FIGURE 16).

Table 2:

Release Rate Data ( $\mu\text{g}/\text{cm}^2/\text{hr}$ )				
Time (days)	Ex. 4a	Ex. 4b	Ex. 5	Ex. 6
0.0	75.26	61.51	23.66	63.96
0.8	14.54	16.80	6.68	22.14
3.1	5.75	6.55	3.71	4.76
5.8	3.46	3.97	2.31	2.19
8.1	2.02	2.65	1.61	1.27
10.1	1.64	2.22	1.27	0.85
12.9	1.48	2.02	1.34	1.41
16.1	1.48	1.94	1.25	1.59
19.8	1.30	1.81	1.12	0.71
22.8	1.05	1.45	0.96	0.57
27.8	0.89	1.29	0.83	0.46
30.8	0.81	1.16	0.72	0.47
37.9	0.70	1.05	0.65	0.33

#### Example 5

[0036] A silicone dispersion containing 4% silicone in THF was prepared. Also prepared was a 10% solution of DEX in THF. A stent graft was dipped into the silicone solution first and dried while being rotated for at least 1 minute. The stent was then dipped into the DEX/THF solution and rotated for at least 1 minute to dry the stent. This sequence of dipping and drying was repeated for about 20 times. The last dip was in the silicone solution. After sitting at room temperature for about 1.5 hours, the coated samples were oven cured at 150°C for 1 hour.

[0037] Like the stents in Example 4a and 4b, this sample was also cut into 2 cm pieces and the release rate was studied according to the procedure used in Examples 4a and 4b. The release rate for Example 5 is presented in Table 2 and FIGURE 16. The data shows that the coated samples can provide prolonged drug release.

#### Example 6

[0038] The silicone dispersion of Example 5 was prepared. Also prepared was a 10% solution of DEX in methanol (MeOH), which is a poor solvent for silicone and hence incompatible to silicone. A stent graft was coated according to the method used to prepared Example 5. This sample was cut into 2 cm pieces and the release rate was studied according to the procedure used in Examples 4a and 4b. The release rate for Ex-

ample 6 is presented in Table 2. The data shows that the coated samples can provide prolonged drug release although this sample exhibited a faster initial drug elution rate than Examples 4a, 4b and 5 (see FIGURE 16).

[0039] The description contained herein is for purposes of illustration and not for purposes of limitation. Changes and modifications may be made to the embodiments of the description and still be within the scope of the invention. Furthermore, obvious changes, modifications or variations will occur to those skilled in the art.

#### Claims

1. A method for forming a coating on at least a portion of a medical device for insertion or implantation into the body of a patient wherein the coating comprises at least one coating layer, to release at least one biologically active material therefrom, the method comprising:

a) applying a polymer system substantially free of a biologically active material comprising a polymer and a first solvent to the surface, and  
b) applying a drug system substantially free of any polymer comprising a biologically active material and a second solvent to the surface; wherein steps a) and b) are simultaneously conducted, and said method forms the coating layer which comprises a substantially homogeneous composite of the polymer and the biologically active material.

2. The method of claim 1 wherein steps a) and b) are repeated.

3. The method of claim 1 wherein the medical device is a stent.

4. The method of claim 1 wherein the medical device is a self-expanding stent.

5. The method of claim 1 wherein the first solvent and the second solvent are the same.

6. The method of claim 1 wherein the first solvent and the second solvent are different.

7. The method of claim 1 wherein the polymer is a hydrophobic biostable elastomer.

8. The method of claim 7 wherein the elastomer is selected from the group consisting of silicones, polyurethanes, thermoplastic elastomers, ethylene vinyl acetate copolymers, polyolefin elastomers, EPDM rubbers and polyamide elastomers.

9. The method of claim 1 wherein the biologically ac-

tive material is selected from the group consisting of antithrombotics, anticoagulants, antiplatelet agents, thrombolytics, antiproliferatives, anti-inflammatories, agents that inhibit hyperplasia, smooth muscle cell inhibitors, antibiotics, growth factors, growth factor inhibitors, cell adhesion inhibitors, cell adhesion promoters and drugs that enhance the formation of healthy neointimal tissue.

10. The method of claim 1 wherein the polymer system or drug system is applied by spray coating.
11. The method of claim 1 wherein the biologically active material is dissolved in the second solvent.
12. The method of claim 1 wherein the biologically active material is suspended in the second solvent.
13. The method of claim 1 which further comprises applying a solvent system to the coating layer.
14. The method of claim 1 which further comprises applying a second drug system substantially free of any polymer and comprising a second biologically active material to the surface.
15. An apparatus (2 - Figures 11 - 14) for covering at least a part of a surface of a medical device (8 - Figures 11-14) with a coating, said apparatus (2) comprising:
  - a) a mounting element (4 - Figures 11 - 14) comprising at least one support element (24 - Figures 11 - 14) for mounting the device (8) to the apparatus (2); and
  - b) a spray element (6 - Figures 11 - 14) aligned with said mounting element (4) in a manner which allows the surface of the device (8) to be sprayed, said spray element (6) comprising
    - i) a structural support (14 - Figures 11 - 14) and
    - ii) first (16 - Figures 11 - 14) and second (18 - Figures 11 - 14) spray canisters movably mounted on said structural support (14), wherein said first canister (16) is fluidly connected to a first spray dispenser (20 - Figures 11 - 14) and said second canister (18) is fluidly connected to a second spray dispenser (22 - Figures 11 - 14).
16. The apparatus of claim 15 which further comprises gas sources connected to said first (20) and second (22) spray dispensers.
17. The apparatus of claim 15 wherein said first (16) and second (18) canisters are fixed at a predetermined distance from each other.

18. The apparatus of claim 15 wherein said first (16) and second (18) canisters are capable of movement independent of each other.

19. The apparatus of claim 15 wherein said first (16) and second (18) canisters are movably mounted on said structural support (14) in a manner which permits said canisters (16, 18) to move past one another.

20. The apparatus of claim 15 which further comprises a motor (10) for rotating said support element (24).

## 15 Revendications

1. Procédé de formation d'une couche sur au moins une partie d'un dispositif médical pour insertion ou implantation dans le corps d'un patient, dans lequel la couche comprend au moins un niveau de couche, pour délivrer au moins un matériau biologiquement actif à partir de là, le procédé comprenant les étapes consistant à :

a) appliquer un système polymère sensiblement libre d'un matériau biologiquement actif comprenant un polymère et un premier solvant sur la surface, et

b) appliquer un système d'agent médicinal sensiblement libre de tout polymère comprenant un matériau biologiquement actif et un deuxième solvant sur la surface ;

dans lequel les étapes a) et b) sont conduites simultanément, et ledit Procédé forme le niveau de couche qui comprend un composite sensiblement homogène du polymère et du matériau biologiquement actif.

2. Procédé selon la revendication 1 dans lequel les étapes a) et b) sont répétées.

3. Procédé selon la revendication 1 dans lequel le dispositif médical est un stent.

4. Procédé selon la revendication 1 dans lequel le dispositif médical est un stent auto-expansif.

5. Procédé selon la revendication 1 dans lequel le premier solvant et le deuxième solvant sont les mêmes.

6. Procédé selon la revendication 1 dans lequel le premier solvant et le deuxième solvant sont différents.

7. Procédé selon la revendication 1 dans lequel le polymère est un élastomère hydrophobe biostable.

8. Procédé selon la revendication 7 dans lequel l'élastomère est sélectionné dans le groupe composé des silicones, des polyuréthanes, des élastomères thermoplastiques, des copolymères d'éthylène-acétate de vinyle, des élastomères polyoléfiniques, des caoutchoucs EPDM et des élastomères polyamides. 5
9. Procédé selon la revendication 1 dans lequel le matériau biologiquement actif est sélectionné dans le groupe composé des antithrombotiques, des anticoagulants, des agents antiplaquettaires, des thrombolytiques, des antiprolifératifs, des anti-inflammatoires, des agents qui inhibent l'hyperplasie, des inhibiteurs des fibres musculaires lisses, des antibiotiques, des facteurs de croissance, des inhibiteurs des facteurs de croissance, des inhibiteurs de l'adhésion cellulaire, des promoteurs de l'adhésion cellulaire et des agents médicaux qui améliorent la formation du tissu néo-intimal sain. 10
10. Procédé selon la revendication 1 dans lequel le système polymère ou le système d'agent médicamenteux est appliqué par pulvérisation de couche. 15
11. Procédé selon la revendication 1 dans lequel le matériau biologiquement actif est dissout dans le deuxième solvant. 20
12. Procédé selon la revendication 1 dans lequel le matériau biologiquement actif est suspendu dans le deuxième solvant. 25
13. Procédé selon la revendication 1 qui comprend en outre l'application d'un système de solvant sur le niveau de couche. 30
14. Procédé selon la revendication 1 qui comprend en outre l'application d'un deuxième système d'agent médicamenteux sensiblement libre de tout polymère et comprenant un deuxième matériau biologiquement actif sur la surface. 35
15. Appareil (2 - Figures 11 - 14) pour couvrir au moins une partie d'une surface d'un dispositif médical (8 - Figures 11 - 14) avec une couche, ledit appareil (2) comprenant : 40
- a) un élément de montage (4 - Figures 11-14) comprenant au moins un élément de support (24-Figures 11 14) pour monter le dispositif (8) sur l'appareil (2) ; et 45
  - b) un élément de pulvérisation (6 - Figures 11 - 14) aligné avec ledit élément de montage (4) afin de permettre de pulvériser la surface du dispositif (8), ledit élément de pulvérisation (6) comprenant : 50
- i. un support structurel (14 - Figures 11-14) et
  - ii. la première (16 - Figures 11 14) et la deuxième (18 - Figures 11 - 14) bouteille de pulvérisation montées de manière déplaçable sur ledit support structurel (14), dans lesquelles ladite première bouteille de pulvérisation (16) est reliée hermétiquement à un premier distributeur de pulvérisation (20-Figures 11 - 14) et ladite deuxième bouteille (18) est reliée à un deuxième distributeur de pulvérisation (22-Figures 11 - 14).
16. Appareil selon la revendication 15 qui comprend en outre des sources gazeuses reliées audit premier (20) et audit deuxième (22) distributeur de pulvérisation. 55
17. Appareil selon la revendication 15 dans lequel ladite première (16) et ladite deuxième (18) bouteille sont fixées à une distance prédéterminée l'une de l'autre. 60
18. Appareil selon la revendication 15 dans lequel ladite première (16) et ladite deuxième (18) bouteille sont capables de se déplacer indépendamment l'une de l'autre. 65
19. Appareil selon la revendication 15 dans lequel ladite première (16) et ladite deuxième (18) bouteille sont montées de manière déplaçable sur ledit support structurel (14) de manière à permettre aux dites bouteilles (16, 18) de passer l'une devant l'autre. 70
20. Appareil selon la revendication 15 qui comprend en outre un moteur (10) pour faire pivoter ledit élément de support (24). 75

#### Patentansprüche

1. Verfahren zum Bilden einer Beschichtung auf mindestens einem Teil einer medizinischen Vorrichtung zum Einschub oder zur Implantation in den Körper eines Patienten, wobei die Beschichtung mindestens eine Beschichtungsschicht zum Freisetzen von mindestens einem biologischen Wirkstoff daraus umfasst, wobei das Verfahren umfasst:
- a) Auftragen eines Polymersystems, im Wesentlichen frei von einem biologischen Wirkstoff, umfassend ein Polymer und ein erstes Lösungsmittel, auf die Oberfläche und
  - b) Auftragen eines Arzneimittelsystems, im Wesentlichen frei von jeglichem Polymer, umfassend einen biologischen Wirkstoff und ein zweites Lösungsmittel auf die Oberfläche,



- wobei Schritte a) und b) gleichzeitig durchgeführt werden und das Verfahren die Beschichtungsschicht bildet, die einen im Wesentlichen homogenen Verbundwerkstoff aus dem Polymer und den biologischen Wirkstoff umfasst.
2. Verfahren nach Anspruch 1, wobei Schritte a) und b) wiederholt werden.
  3. Verfahren nach Anspruch 1, wobei die medizinische Vorrichtung einen Stent darstellt.
  4. Verfahren nach Anspruch 1, wobei die medizinische Vorrichtung einen sich selbst ausdehnenden Stent darstellt.
  5. Verfahren nach Anspruch 1, wobei das erste Lösungsmittel und das zweite Lösungsmittel die gleichen sind.
  6. Verfahren nach Anspruch 1, wobei das erste Lösungsmittel - und das zweite Lösungsmittel verschieden sind.
  7. Verfahren nach Anspruch 1, wobei das Polymer ein hydrophobes biostabiles Elastomer darstellt.
  8. Verfahren nach Anspruch 7, wobei das Elastomer ausgewählt ist aus der Gruppe, bestehend aus Siliconen, Polyurethanen, thermoplastischen Elastomeren, Ethylenvinylacetat-Copolymeren, Polyolefinelastomeren, EPDM-Kautschuken und Polyamidelastomeren.
  9. Verfahren nach Anspruch 1, wobei der biologische Wirkstoff ausgewählt ist aus der Gruppe, bestehend aus antitrombotischen Mitteln, Gerinnungshemmern, Antitrombozytenmitteln, Thrombolytika, antiproliferativen Mitteln, entzündungshemmenden Mitteln, Mitteln, die Hyperplasie inhibieren, Glattmuskellinhibitoren, Antibiotika, Wachstumsfaktoren, Wachstumsfaktorinhibitoren, Zellanhaftungsinhibitoren, Zellanhaftungspromotoren und Arzneimitteln, die die Bildung von gesundem neointimalem Gewebe verstärken.
  10. Verfahren nach Anspruch 1, wobei das Polymersystem oder Arzneimittelsystem durch Sprühbeschichtung aufgetragen wird.
  11. Verfahren nach Anspruch 1, wobei der biologische Wirkstoff in dem zweiten Lösungsmittel gelöst wird.
  12. Verfahren nach Anspruch 1, wobei der biologische Wirkstoff in dem zweiten Lösungsmittel suspendiert wird.
  13. Verfahren nach Anspruch 1, das weiterhin Auftragen eines Lösungsmittelsystems auf die Beschichtungsschicht umfasst.
  14. Verfahren nach Anspruch 1, das weiterhin Auftragen eines zweiten Arzneimittelsystems, im Wesentlichen frei von jeglichem Polymer und umfassend einen zweiten biologischen Wirkstoff, auf die Oberfläche umfasst.
  15. Apparatur (2 - Figuren 11-14) zum Bedecken von mindestens einem Teil einer Oberfläche einer medizinischen Vorrichtung (8 - Figuren 11-14) mit einer Beschichtung, wobei die Apparatur (2) umfasst:
    - a) ein Befestigungselement (4 - Figuren 11-14), umfassend mindestens ein Trägerelement (24 - Figuren 11-14) zum Befestigen der Vorrichtung (8) an der Apparatur (2) und
    - b) ein Sprühelement (6 - Figuren 11-14), ausgerichtet mit dem Befestigungselement (4) in einer Weise, die erlaubt, dass die Oberfläche der Vorrichtung (8) besprüht wird, wobei das Sprühelement (6) umfasst
      - i) einen Strukturträger (14 - Figuren 11-14) und
      - ii) erste (16 - Figuren 11-14) und zweite (18 - Figuren 11-14) Sprühkanister, die beweglich an dem Strukturträger (14) befestigt sind, wobei der erste Kanister (16) fluid mit dem ersten Sprühdosierer (20 - Figuren 11-14) verbunden ist und der zweite Kanister (18) fluid mit einem zweiten Sprühdosierer (22 - Figuren 11-14) verbunden ist.
  16. Apparatur nach Anspruch 15, die weiterhin Gasquellen umfasst, die mit den ersten (20) und zweiten (22) Sprühdosierern verbunden sind.
  17. Apparatur nach Anspruch 15, wobei die ersten (16) und zweiten (18) Kanister bei einem vorbestimmten Abstand von einander befestigt sind.
  18. Apparatur nach Anspruch 15, wobei die ersten (16) und zweiten (18) Kanister unabhängig voneinander bewegt werden können.
  19. Apparatur nach Anspruch 15, wobei die ersten (16) und zweiten (18) Kanister beweglich auf dem Strukturträger (14) in einer Weise befestigt sind, dass die Kanister (16, 18) nacheinander bewegt werden können.
  20. Apparatur nach Anspruch 15, die weiterhin einen Motor (10) zum Rotieren des Trägerelements (24) umfasst.



FIG. 1




FIG. 2




FIG. 3



FIG.4



FIG.5



FIG.6



FIG.7






FIG.8



FIG.9



**FIG. 10**







FIG.12








FIG. 14




FIG.15




FIG.16